Comparing dosimetric, morbidity, quality of life, and cancer control outcomes after 3d conformal, intensity-modulated, and proton radiation therapy for prostate cancer

Seminars in Radiation Oncology

Volumn 23, Issue 3, 2013, Pages 182-190

  Pearlstein, Kevin A ^a   Chen, Ronald C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CONTROL; DOSIMETRY; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIATION HAZARD; REVIEW; TREATMENT OUTCOME;

HUMANS; MALE; PROSTATIC NEOPLASMS; PROTON THERAPY; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 84878825770     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.01.004     Document Type: Review

References (78)

1. Warde P., Mason M., Ding K., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 2011, 378:2104-2111.
2. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 2009, 373:301-308.
3. Lawton C.A., Won M., Pilepich M.V., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991, 21:935-939.
4. Schultheiss T.E., Hanks G.E., Hunt M.A., et al. Incidence of and factors related to late complications in conformal and conventional radiation TREATMENT of CANCER of the prostate. Int J Radiat Oncol Biol Phys 1995, 32:643-649.
5. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol 2010, 28:1106-1111.
6. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
7. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
8. Luxton G., Hancock S.L., Boyer A.L. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2004, 59:267-284.
9. Nutting C.M., Convery D.J., Cosgrove V.P., et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000, 48:649-656.
10. Palma D., Vollans E., James K., et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: Comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:996-1001.
11. Mock U., Bogner J., Georg D., et al. Comparative treatment planning on localized prostate carcinoma conformal photon-versus proton-based radiotherapy. Strahlenther Onkol 2005, 181:448-455.
12. Kao J., Turian J., Meyers A., et al. Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. Br J Radiol 2004, 77:129-136.
13. De Meerleer G.O., Vakaet L.A., De Gersem W.R., et al. Radiotherapy of prostate cancer with or without intensity modulated beams: A planning comparison. Int J Radiat Oncol Biol Phys 2000, 47:639-648.
14. Hardcastle N., Davies A., Foo K., et al. 2010: Rectal dose reduction with IMRT for prostate radiotherapy. J Med Imaging Radiat Oncol 2010, 54:235-248.
15. Michalski J.M., Yan Y., Watkins-Bruner D., et al. Preliminary analysis of 3D-CRT vs. IMRT on the high dose arm of the RTOG 0126 prostate cancer trial: Toxicity report. Int J Radiat Oncol Biol Phys 2011, 81:S1-S2.
16. Wang-Chesebro A., Xia P., Coleman J., et al. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66:654-662.
17. Ashman J.B., Zelefsky M.J., Hunt M.S., et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:765-771.
18. Cella L., Lomax A., Miralbell R. Potential role of intensity modulated proton beams in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2001, 49:217-223.
19. Sheets N.C., Goldin G.H., Meyer A.M., et al. Intensity-modulated Radiation therapy, proton therapy, or conformal Radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012, 307:1611-1620.
20. Zietman A.L. The titanic and the iceberg: Prostate proton therapy and health care economics. J Clin Oncol 2007, 25:3565-3566.
21. MacReady N. The promise of protons in cancer therapy. J Natl Cancer Inst 2012, 104:648-649.
22. Nguyen P.L., Trofimov A., Zietman A.L. Proton-beam vs intensity-modulated radiation therapy-Which is best for treating prostrate cancer?. Oncology (Williston Park) 2008, 22:748-754.
23. Lomax A. Intensity modulation methods for proton radiotherapy. Phys Med Biol 1999, 44:185-205.
24. Chera B.S., Vargas C., Morris C.G., et al. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009, 75:994-1002.
25. Trofimov A., Nguyen P.L., Coen J.J., et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: A treatment planning comparison. Int J Radiat Oncol Biol Phys 2007, 69:444-453.
26. Vargas C., Fryer A., Mahajan C., et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:744-751.
27. Luo W., Li J., Fourkal E., et al. Dosimetric advantages of IMPT over IMRT for laser-accelerated proton beams. Phys Med Biol 2008, 53:7151-7166.
28. Weber D.C., Wang H., Cozzi L., et al. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: A treatment planning comparison study. Radiat Oncol 2009, 4:11.
29. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensions conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999, 85:2460-2468.
30. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
31. Al-Mamgani A., van Putten W.L., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:980-988.
32. Fiorino C., Fellin G., Rancati T., et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: Preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys 2008, 70:1130-1137.
33. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II: Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 2001, 49:685-698.
34. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000, 47:103-113.
35. Tucker S.L., Dong L., Cheung R., et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60:1589-1601.
36. Vargas C., Martinez A., Kestin L.L., et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:1297-1308.
37. Wachter S., Gerstner N., Goldner G., et al. Rectal sequelae after conformal radiotherapy of prostate cancer: Dose-volume histograms as predictive factors. Radiother Oncol 2001, 59:65-70.
38. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000, 48:635-642.
39. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129.
40. Al-Mamgani A., Heemsbergen W.D., Peeters S.T., et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:685-691.
41. Sharma N.K., Li T., Chen D.Y., et al. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80:437-444.
42. Dolezel M., Odrazka K., Vaculikova M., et al. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: Direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 2010, 186:197-202.
43. Alongi F., Fiorino C., Cozzarini C., et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009, 93:207-212.
44. Bekelman J.E., Mitra N., Efstathiou J., et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81:e325-e334.
45. Kim S., Shen S., Moore D.F., et al. Late gastrointestinal toxicities following Radiation therapy for prostate cancer. Eur Urol 2011, 60:908-916.
46. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166:876-881.
47. Gardner B.G., Zietman A.L., Shipley W.U., et al. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 2002, 167:123-126.
48. Viswanathan A.N., Yorke E.D., Marks L.B., et al. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010, 76:S116-S122.
49. Coen J.J., Bae K., Zietman A.L., et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: Initial report of American college of radiology phase II study 03-12. Int J Radiat Oncol Biol Phys 2011, 81:1005-1009.
50. Mendenhall N.P., Li Z., Hoppe B.S., et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:213-221.
51. Slater J.D., Rossi C.J., Yonemoto L.T., et al. Proton therapy for prostate cancer: The initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 2004, 59:348-352.
52. Zelefsky M.J., Kollmeier M., Cox B., et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 84:125-129.
53. Park S.S., Yan D., McGrath S., et al. Adaptive image-guided radiotherapy (IGRT) eliminates the risk of biochemical failure caused by the bias of rectal distension in prostate cancer treatment planning: Clinical evidence. Int J Radiat Oncol Biol Phys 2012, 83:947-952.
54. Deutschmann H., Kametriser G., Steininger P., et al. First clinical release of an Online, adaptive, aperture-based image-guided radiotherapy strategy in intensity-modulated radiotherapy to correct for inter- and intrafractional rotations of the prostate. Int J Radiat Oncol Biol Phys 2012, 83:1624-1632.
55. Langen K.M., Zhang Y., Andrews R.D., et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol Biol Phys 2005, 62:1517-1524.
56. Litzenberg D.W., Balter J.M., Hadley S.W., et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2006, 65:548-553.
57. Rijkhorst E.J., Van Herk M., Lebesque J.V., et al. Strategy for online correction of rotational organ motion for intensity-modulated radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 69:1608-1617.
58. Nuver T.T., Hoogeman M.S., Remeijer P., et al. An adaptive off-line procedure for radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 67:1559-1567.
59. Chung P.W., Haycocks T., Brown T., et al. On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 2004, 60:329-334.
60. Jensen I., Carl J., Lund B., et al. Radiobiological impact of reduced margins and treatment technique for prostate cancer in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP). Med Dosim 2011, 36:130-137.
61. Nairz O., Merz F., Deutschmann H., et al. Eine Strategie zum Einsatz bildgefuhrter Radiotherapie an Linearbeschleunigern und ihr Einfluss auf Sicherheitsrander fur Prostatakarzinompatienten. Strahlenther Onkol 2008, 184:663-667.
62. van Haaren P.M., Bel A., Hofman P., et al. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiother Oncol 2009, 90:291-298.
63. Wertz H., Lohr F., Dobler B., et al. Dosimetric consequences of a translational isocenter correction based on image guidance for intensity modulated radiotherapy (IMRT) of the prostate. Phys Med Biol 2007, 52:5655-5665.
64. Wertz H., Lohr F., Dobler B., et al. Dosimetric impact of image-guided translational isocenter correction for 3-d conformal radiotherapy of the prostate. Strahlenther Onkol 2007, 183:203-210.
65. Ghilezan M., Yan D., Liang J., et al. Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect?. A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery. Int J Radiat Oncol Biol Phys 2004, 60:1602-1610.
66. Crehange G., Mirjolet C., Gauthier M., et al. Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiother Oncol 2012, 103:244-246.
67. Bohrer M., Schröder P., Welzel G., et al. Reduzierte Rektumtoxizitat mit bildgestutzter Radiotherapie mittels BAT (TM) (B-Mode Acquisition and Targeting-System) beim Prostatakarzinom. Strahlenther Onkol 2008, 184:674-678.
68. Litwin M.S., Lubeck D.P., Henning J.M., et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol 1998, 159:1988-1992.
69. Namiki S., Ishidoya S., Ito A., et al. Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer. Jpn J Clin Oncol 2009, 39:732-738.
70. Yoshimura K., Kamoto T., Nakamura E., et al. Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: Intensity-modulated radiation therapy versus conformal radiation therapy. Prostate Cancer Prostatic Dis 2007, 10:288-292.
71. Pinkawa M., Piroth M.D., Holy R., et al. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 2011, 187:479-484.
72. Lips I., Dehnad H., Kruger A.B., et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 GY intensity-modulated radiotherapy vs. 70 GY conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 2007, 69:656-661.
73. Bruner D.W., Hunt D., Michalski J.M., et al. Preliminary analysis of 3D-CRT vs. IMRT on the high dose arm of the RTOG 0126 prostate cancer trial: Patient reported outcomes. Int J Radiat Oncol Biol Phys 2011, 81. S44-S44.
74. Sandler H.M., Liu P.Y., Dunn R.L., et al. Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: Assessing the impact of margin reduction study. Urology 2010, 75:1004-1008.
75. Talcott J.A., Rossi C., Shipley W.U., et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon Radiation for early prostate cancer. JAMA 2010, 303:1046-1053.
76. Mendenhall W.M., Henderson R.H., Indelicato D.J., et al. Erectile dysfunction after radiotherapy for prostate cancer. Am J Clinical Oncol 2009, 32:443-447.
77. Vora S.A., Wong W.W., Schild S.E., et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:1053-1058.
78. Spratt D.E., Pei X., Yamada J., et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 85:686-692.